
Pharmaceutical firm MSD is reported interested in buying US-based biotech firm Seagen, anonymous sources have told media Dow Jones News.
Following the rumors, Seagen shares increased by 16.9% to USD 171.6 on the stock exchange.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app